Clarendon Press, Oxford, pp
The SURMOUNT-4 trial assessed the weight maintenance with tirzepatide and had also two periods: a 36-week open-label lead-in period during which all participants took tirzepatide, followed by a 52-week double-blind treatment period during which participants were randomised to either continue on tirzepatide or switch to placebo
What to expect if you stop your GLP-1 medication Understanding the discontinuation timeline is just as important as understanding the onset timeline, because many people will eventually stop or pause their medication
Clinical indications for anticoagulation therapy include atrial fibrillation, mechanical heart valves, deep venous thrombosis, and dilated cardiomyopathies
(4) peripheral immune cells such as macrophages, T-lymphocytes, and monocytes may gain access to the CNS and release the inflammatory mediators
Brussels, Belgium: 2015